 |
|
 |
|
|
Talecris continues to expand its range of innovative programs and services to better meet the needs of our customers.
| Prolastin Direct™ |
|
Prolastin Direct™ is a unique delivery service designed to help patients get the medicine they need, when and where they need it. With Prolastin Direct™, a patient's medication goes wherever the patient goes.
To enroll and learn more about this service call 1-800-305-7881.
|
| Precision Pharma Services |
|
Precision Pharma offers development, manufacturing, packaging, and testing services for clinical, small-scale, and commercial-stage products — specializing in sterile pharmaceutical, biopharmaceutical, and complex biological finished products.
www.precisionpharma.com
|
| Talecris Plasma Resources |
|
Talecris Plasma Resources, Inc. (TPR) is a newly formed company specializing in the collection of human plasma. Because human plasma is used to manufacture therapies that save and extend people's lives, Talecris Plasma Resources has an uncompromising commitment to quality and strict adherence to all regulations and guidelines governing plasma collection.
www.talecrisplasma.com
|
| Talecris Talents Grant Program |
|
The Talecris New Trials Support (Talents) program is an initiative supporting investigator-initiated trials conceived by researchers and clinicians with an interest in intravenous immunoglobulin (IGIV) therapies. Each year, Talecris pledges $1 million to fund basic science and clinical research projects in various fields, including immunology, hematology, and neurology.
www.talecristalents.com
|
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|
|
|
|
|